Who are MAZ-101association's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pf-06823859, Pf-06865571, Praga formulation, Pembrolizumab/Vibostolimab Co-Formulation, TQB2303, Investigational products administration.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/maz-101association.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

MAZ-101association — Competitive Intelligence Brief

MAZ-101association (MAZ-101association) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1/PD-L1 inhibitor. Area: Oncology.

phase 3 PD-1/PD-L1 inhibitor PD-1/PD-L1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

MAZ-101association (MAZ-101association) — EMS. MAZ-101association is a drug that targets the PD-1/PD-L1 pathway to modulate the immune response.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MAZ-101association TARGET	MAZ-101association	EMS	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1
Pf-06823859	pf-06823859	Pfizer	marketed	Monoclonal Antibody	PD-1/PD-L1
Pf-06865571	pf-06865571	Pfizer	marketed	Monoclonal antibody	PD-1/PD-L1 pathway
Praga formulation	Praga formulation	EMS	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1
Pembrolizumab/Vibostolimab Co-Formulation	Pembrolizumab/Vibostolimab Co-Formulation	Merck Sharp & Dohme LLC	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1
TQB2303	TQB2303	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1
Investigational products administration	Investigational products administration	Assistance Publique - Hôpitaux de Paris	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1/PD-L1 inhibitor class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 3 drugs in this class
AstraZeneca · 2 drugs in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Hanlim Pharm. Co., Ltd. · 1 drug in this class
EMD Serono · 1 drug in this class
EMS · 1 drug in this class
Fujian Cancer Hospital · 1 drug in this class
Elixiron Immunotherapeutics (Hong Kong) Ltd. · 1 drug in this class
Cellvax Therapeutics Inc · 1 drug in this class
Anhui Shi, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MAZ-101association — Competitive Intelligence Brief. https://druglandscape.com/ci/maz-101association. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab